Recombinant proteins represent a cornerstone of modern biopharmaceutical innovation, enabling breakthroughs across diverse therapeutic applications. At our cutting-edge facilities, we deliver end-to-end contract development and manufacturing organization (CDMO) solutions tailored to these complex molecules. We accelerate your journey from concept to commercialization. Explore our broader capabilities in CDMO Solutions and specialized support in Biologic CDMO Solutions.
Recombinant Protein CDMO Solutions: Strategic Advantages
Recombinant protein therapeutics demand precision in development and manufacturing due to their structural complexity and sensitivity. Our CDMO solutions address these challenges through integrated expertise in molecular biology, process engineering, and regulatory compliance. We optimize expression systems, purification protocols, and analytical methods to ensure high yield, purity, and bioactivity. This holistic approach transforms scientific potential into viable, high-quality products.
Our Recombinant Protein CDMO Solutions
Building upon our strategic advantages, we deliver an integrated suite of CDMO services engineered specifically for recombinant protein therapeutics. Our end-to-end solutions navigate the unique complexities of these molecules through scientifically rigorous, phase-appropriate development and manufacturing.
Cell Line Development and Optimization
We engineer high-performance cell lines using advanced host systems (CHO, E. coli, yeast) tailored to target protein characteristics. Our platform integrates codon optimization, vector design, and high-throughput screening to identify clones with superior expression titers, stability, and growth kinetics. Moreover, our gene-editing technologies minimize undesirable post-translational modifications while enhancing productivity.
Process Development and Scale-Up
Our upstream team optimizes fermentation parameters through media design, feeding strategies, and bioreactor control (batch, fed-batch, perfusion). Downstream, we develop purification trains incorporating affinity chromatography, viral clearance steps, and refolding protocols for insoluble proteins. Process analytical technology (PAT) enables real-time monitoring, facilitating smooth tech transfer to commercial-scale manufacturing.
Analytical Development and Characterization
We deploy state-of-the-art methodologies for identity, purity, potency, and stability assessments. Our capabilities include:
- Primary Structure Analysis: Peptide mapping, intact mass analysis via LC-MS.
- Higher-Order Structure: Circular dichroism, FTIR spectroscopy.
- Functional Characterization: Cell-based bioassays, binding kinetics (SPR/BLI).
- Glycosylation Profiling: HILIC-UPLC, enzymatic release workflows.
cGMP Manufacturing
Flexible manufacturing suites can support the clinical production of recombinant proteins up to the commercial-scale production. The main features of the manufacturing suites include:
- Single-use bioreactors and automated purification skids.
- Dedicated viral clearance suites.
- Closed processing systems.
- Continuous bioburden monitoring.
- Rigorous changeover protocols.
We offer comprehensive recombinant protein CDMO solutions, covering the full development lifecycle from early-stage cell line development and process optimization to clinical and commercial production. Our recombinant protein CDMO expertise accelerates your biopharmaceutical goals through science-driven innovation and regulatory excellence. Partner with us for reliable, scalable solutions—contact our team to initiate your project.
Frequently Asked Questions
Q1: What host systems do you recommend for complex recombinant proteins?
We select hosts based on protein properties: mammalian cells (e.g., CHO) for glycosylation-dependent molecules, microbial systems for simpler proteins. Our screening platform identifies optimal candidates balancing yield, cost, and quality.
Q2: How do you manage post-translational modification (PTM) consistency?
PTM control begins with clone screening and extends to process optimization. We use glycoengineering, media additives, and in-process analytics to minimize heterogeneity, ensuring batch-to-batch uniformity.
Our products and services are for research use only.
